newsfilter
← Latest News
PR Newswire·

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

- Top line results expected during the fourth quarter of 2022 - Data Safety Monitoring Board has confirmed no adverse safety issues NEW YORK, April 19, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmac